CA
BMY.RT

Crewe Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Crewe Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-16
Closed – – 646
2020
Q2 		$0 Hold
16
– – ﹤0.01% 237
2020
Q1 		$0 Hold
16
– – ﹤0.01% 267
2019
Q4 		$0 Buy
+16
New +$42 ﹤0.01% 290

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Crewe Advisors's BMY.RT Position: Q3 2020 in Review

Crewe Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 16 shares.

Crewe Advisors first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $0 in Q2 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Crewe Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • Crewe Advisors sold 16 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020.
  • Crewe Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • Crewe Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $0 in Q2 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Crewe Advisors's 13F filing for Q3 2020, filed 13 Oct 2020.